Kate Nichols

Cooley advised Intersect ENT, a global ear, nose and throat medical technology leader dedicated to transforming patient care, on its agreement to sell to medical technology company Medtronic in an all-cash transaction valued at $1.1 billion. Lawyers Steve Tonsfeldt, Matthew Hemington, Kevin Cooper and Matthew Silverman led the Cooley team advising Intersect ENT.

Cooley advised Snowflake on its $3.9 billion initial public offering of 32,200,000 Class A shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Snowflake, whose securities now trade on the New York Stock Exchange under the symbol “SNOW,” is a cloud software company pioneering the data cloud, an ecosystem where customers, partners and data providers can break down data silos and derive value from rapidly growing data sets in secure, governed and compliant ways. Partners Mark Tanoury, Jon Avina and Seth Gottlieb led the Cooley team.

Cooley advised edge cloud platform provider Fastly on its agreement to acquire Signal Sciences, one of the fastest growing web application security companies in the world, for approximately $775 million in cash and stock. The acquisition will expand Fastly’s robust security portfolio at a time when security at the edge has never been more critical. Partners Ben Beerle, Jamie Leigh and Seth Gottlieb led the Cooley team advising Fastly.

Cooley advised Fastly on its $207 million initial public offering of 12,937,500 shares of common stock. Mark Tanoury, Jon Avina and Seth Gottlieb led the Cooley team advising Fastly.

BofA Merrill Lynch, Citigroup, and Credit Suisse served as joint book-running managers for the offering. William Blair, Raymond James, Baird, Oppenheimer & Co., Stifel, Craig-Hallum Capital Group and D.A. Davidson & Co. served as co-managers for the offering.

Fastly is an edge cloud platform powering online destinations including Airbnb, GitHub, Alaska Airlines, Pinterest, Vimeo, The Guardian, and The New York Times. The company’s shares now trade on the NYSE under the symbol “FSLY.”

Cooley advised Si-Bone on its $124.2 million initial public offering of 8,280,000 shares of common stock. Matthew Hemington and John McKenna led the Cooley team advising Si-Bone.

Morgan Stanley and Merrill Lynch acted as the lead book-running managers for the offering. Canaccord Genuity and JMP Securities acted as co-managers for the offering.

Si-Bone is a medical device company that has pioneered a treatment for sacroiliac joint dysfunction that often causes severe lower back pain. The company’s shares now trade on the Nasdaq Global Market under the symbol “SIBN.”